BerandaBHC • NYSE
Bausch Health Companies Inc
$7,56
13 Jan, 12.09.32 GMT-5 · USD · NYSE · Pernyataan Penyangkalan
SahamSekuritas terdaftar di Amerika SerikatBerkantor pusat di CA
Tutup sebelumnya
$7,88
Rentang hari
$7,45 - $7,80
Rentang tahun
$3,96 - $11,46
Kapitalisasi pasar
2,73 M USD
Volume Rata-Rata
1,27 jt
Rasio P/E
-
Hasil dividen
-
Skor Perubahan Iklim CDP
D
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD)Sep 2024Perubahan Y/Y
Pendapatan
2,51 M12,15%
Biaya operasional
1,27 M13,29%
Laba bersih
-85,00 jt77,51%
Margin laba bersih
-3,3979,93%
Penghasilan per saham
1,129,34%
EBITDA
866,00 jt8,93%
Tarif pajak efektif
-338,10%—
Total aset
Total liabilitas
(USD)Sep 2024Perubahan Y/Y
Investasi tunai jangka pdk
719,00 jt-5,39%
Total aset
26,54 M-1,94%
Total liabilitas
26,78 M-1,89%
Total ekuitas
-242,00 jt—
Saham yang beredar
367,80 jt—
Harga terhadap nilai buku
-2,47—
Tingkat pengembalian aset
5,13%—
Tingkat pengembalian modal
6,37%—
Perubahan kas bersih
(USD)Sep 2024Perubahan Y/Y
Laba bersih
-85,00 jt77,51%
Kas dari operasi
405,00 jt43,62%
Kas dari investasi
-102,00 jt94,60%
Kas dari pembiayaan
-189,00 jt-110,41%
Perubahan kas bersih
127,00 jt-33,85%
Arus kas bebas
606,75 jt261,43%
Tentang
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell. Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada. Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Didirikan
1959
Karyawan
20.270
Telusuri
Hapus penelusuran
Tutup penelusuran
Aplikasi Google
Menu utama